Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LinkLab is a South Korean biotechnology company specializing in the development of advanced linker technologies for next-generation therapeutics. Founded in 2021, the company focuses on site-specific conjugation platforms designed to enhance the stability, efficacy, and safety of complex modalities such as Antibody-Drug Conjugates (ADCs) and Proteolysis-Targeting Chimeras (PROTACs). By optimizing the chemical bridges between targeting moieties and therapeutic payloads, LinkLab aims to overcome current limitations in drug delivery and targeted protein degradation. The company operates as a platform-centric biotech, leveraging its proprietary chemistry to support both internal programs and external collaborations in the oncology space.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LinkLab.